Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study

- Afentakis, Maria, Dowsett, Mitch, Sestak, Ivana, Salter, Janine, Howell, Tony, Buzdar, Aman, Forbes, John, Cuzick, Jack

HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

- Bartlett, John M. S., Ahmed, Ikhlaaq, Brookes, Cassandra L., Forbes, John F., Viale, Giuseppe, Cuzick, Jack, Dowsett, Mitchell, Rea, Daniel W., Regan, Meredith M., Sestak, Ivana, Mallon, Elizabeth A., Dell'Orto, Patrizia, Thürlimann, Beat, Seynaeve, Caroline, Putter, Hein, Van de Velde, Cornelis J. H.

Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study

- Cuzick, Jack, Warwick, Jane, Pinney, Elizabeth, Duffy, Stephen W., Cawthorn, Simon, Howell, Anthony, Forbes, John F., Warren, Ruth M. L.

Preventive therapy for breast cancer: a consensus statement

- Cuzick, Jack, DeCensi, Andrea, Vogel, Victor, Zwierzina, Heinz, Arun, Banu, Brown, Powell H., Castiglione, Monica, Dunn, Barbara, Forbes, John F., Glaus, Agnes, Howell, Anthony, Von Minckwitz , Gunter

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial

- Cuzick, Jack, Sestak, Ivana, Cawthorn, Simon, Hamed, Hisham, Holli, Kaija, Howell, Anthony, Forbes, John F.

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

- Cuzick, Jack, Sestak, Ivana, Mershon, John, Mitlak, Bruce H., Powles, Trevor, Veronesi, Umberto, Vogel, Victor, Wickerham, D. Lawrence, Bonanni, Bernardo, Costantino, Joseph P., Cummings, Steve, DeCensi, Andrea, Dowsett, Mitch, Forbes, John F., Ford, Leslie, LaCroix, Andrea Z.

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

- Cuzick, Jack, Sestak, Ivana, Bonanni, Bernardo, Palva, Tina, Howell, Anthony, Forbes, John F., Dowsett, Mitch, Knox, Jill, Cawthorn, Simon, Saunders, Christobel, Roche, Nicola, Mansel, Robert E., von Minckwitz, Gunter

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer

- Cuzick, Jack, Dowsett, Mitch, Howell, Anthony, Buzdar, Aman U., Forbes, John F., Pineda, Silvia, Wale, Christopher, Salter, Janine, Quinn, Emma, Zabaglo, Lila, Mallon, Elizabeth, Green, Andrew R., Ellis, Ian O.

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial

- Cuzick, Jack, Sestak, Ivana, Pinder, Sarah E., Ellis, Ian O., Forsyth, Sharon, Bundred, Nigel J., Forbes, John F., Bishop, Hugh, Fentiman, Ian S., George, William D.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

- Cuzick, Jack, Sestak, Ivana, Baum, Michael, Buzdar, Aman, Howell, Anthony, Dowsett, Mitch, Forbes, John F.

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC Study

- Dowsett, Mitch, Cuzick, Jack, Howell, Anthony, Bugarini, Roberto, Baehner, Frederick L., Shak, Steven, Wale, Christopher, Forbes, John, Mallon, Elizabeth A., Salter, Janine, Quinn, Emma, Dunbier, Anita, Baum, Michael, Buzdar, Aman

Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer

- Dowsett, Mitch, Sestak, Ivana, Buus, Richard, Lopez-Knowles, Elena, Mallon, Elizabeth, Howell, Anthony, Forbes, John F., Buzdar, Aman, Cuzick, Jack

Predictive algorithms for adjuvant therapy: transATAC

- Dowsett, Mitch, Salter, Janine, Zabaglo, Lila, Mallon, Elizabeth, Howell, Antony, Buzdar, Aman U., Forbes, John, Pineda, S., Cuzick, Jack

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

- Dowsett, Mitch, Cuzick, Jack, Coombes, Charles, Snowdon, Claire, Gnant, Michael, Jakesz, Raimund, Kaufmann, Manfred, Boccardo, Francesco, Godwin, Jon, Davies, Christina, Peto, Richard, Ingle, Jim, Coates, Alan, Forbes, John, Bliss, Judith, Buyse, Marc, Baum, Michael, Buzdar, Aman, Colleoni, Marco

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial

- Dowsett, Mitch, Allred, Craig, Bishop, Hugh, Ellis, Ian, Larsimont, Danis, Sasano, Hironobu, Carder, Pauline, Cussac, Antonio L., Knox, Fiona, Speirs, Valerie, Forbes, John, Buzdar, Aman, Knox, Jill, Quinn, Emma, Salter, Janine, Wale, Chris, Cuzick, Jack, Houghton, Joan, Williams, Norman, Mallon, Elizabeth

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial

- Forbes, John F., Sestak, Ivana, Holcombe, Chris, Coleman, Robert E., Jones, Louise, Ellis, Ian, Cuzick, Jack, Howell, Anthony, Bonanni, Bernardo, Bundred, Nigel, Levy, Christelle, von Minckwitz, Gunter, Eiermann, Wolfgang, Neven, Patrick, Stierer, Michael

Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the arimidex, tamoxifen alone or in combination trial

- Ring, Alistair, Sestak, Ivana, Baum, Michael, Howell, Anthony, Buzdar, Aman, Dowsett, Mitch, Forbes, John F., Cuzick, Jack

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis

- Sestak, Ivana, Cuzick, Jack, Sapunar, Francisco, Eastell, Richard, Forbes, John F., Bianco, Angelo R., Buzdar, Aman U.

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial

- Sestak, Ivana, Singh, Shalini, Eastell, Richard, Cuzick, Jack, Blake, Glen M., Patel, Rajesh, Gossiel, Fatma, Coleman, Rob, Dowsett, Mitch, Forbes, John F., Howell, Anthony

Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial

- Sestak, Ivana, Distler, Wolfgang, Forbes, John F., Dowsett, Mitch, Howell, Anthony, Cuzick, Jack